Editorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
Authors:
Open Access
- 29 October 2026
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 2004605
Abstract
Chronic large-vessel occlusion is best understood not as a static angiographic finding but as a dynamic cerebrovascular state in which anatomy, collateral adaptation, hemodynamic reserve, tissue vulnerability, and treatment strategy interact over time. This distinction matters clinically. Hemodynamic impairment has been associated with recurrent ischemic risk in carotid occlusive disease (1), yet randomized trials of extracranial-intracranial bypass, including COSS and CMOSS, have not demonstrated an overall benefit over medical therapy in selected patients with symptomatic carotid or middle cerebral artery occlusion (2,3). Meanwhile, advances in endovascular recanalization have renewed interest in carefully selected patients with chronic occlusion, although the evidence remains largely observational (4). These apparently conflicting observations point to a central challenge: the presence of an occluded artery alone is insufficient to identify who will deteriorate, who may benefit from revascularization, and who may be harmed by intervention. Patients with similar angiographic lesions may have markedly different clinical trajectories depending on collateral sufficiency and residual perfusion. Accordingly, diagnosis should move beyond defining the site and length of occlusion toward characterizing its physiological consequences and the viability of the threatened vascular territory.The contributions to this Research Topic, taken together, extend beyond chronic occlusion itself and support a more useful continuum-based framework for large-vessel occlusive disease-from vascular remodeling and collateral compensation, through patient selection and revascularization, to procedural execution and post-reperfusion recovery. Collateral biology is a logical starting point. Li et al. review postoperative collateral formation in moyamoya disease, a prototypical chronic progressive steno-occlusive arteriopathy, and highlight the interplay of genetic susceptibility, angiogenic signaling, cellular mechanisms, and clinical factors. Their synthesis reinforces an important concept: successful revascularization depends not only on restoring a conduit for blood flow, but also on the biological capacity of the cerebral circulation to adapt. This is consistent with contemporary views of moyamoya disease as a heterogeneous disorder in which mechanisms, hemodynamics, and response to revascularization vary substantially across patients (5). For chronic large-vessel occlusion more broadly, anatomical severity should therefore be interpreted together with collateral status, perfusion, and cerebrovascular reserve rather than in isolation.A second theme is the transition from a binary question-whether to revascularize-to a more precise question: which patient, which lesion, and which strategy? Qureshi et al. explored a potentially higher-risk subgroup of patients with extracranial vertebral artery stenosis treated soon after ischemic stroke. The primary vertebrobasilar stroke/death endpoint did not reach conventional statistical significance, although exploratory outcomes favored stenting, appropriately framing the findings as hypothesis-generating rather than definitive. This nuance is important because pooled randomized evidence has continued to show uncertainty regarding the clinical benefit of vertebral artery stenting (6) We therefore view the central message of this Research Topic as one of precision rather than procedural expansion. Future studies should standardize definitions of chronicity and technical success, quantify hemodynamic failure and collateral capacity, distinguish embolic from lowflow mechanisms, and prospectively validate multimodal models that integrate vascular anatomy, perfusion, clinical phenotype, and biological markers. Most importantly, chronic occlusionspecific evidence still requires prospective multicenter cohorts and randomized studies capable of identifying treatment-responsive subgroups. The goal is not simply to reopen an artery. It is to determine when restoring flow can be achieved safely, for the right mechanism and the right patient, and translated into durable neurological benefit.Keywords
This publication has 6 references indexed in Scilit:
- Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke AssociationStroke, 2023
- Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery OcclusionJAMA, 2023
- A systematic review of endovascular treatment for chronic total occlusion of the internal carotid arteryAnnals of Translational Medicine, 2021
- Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysisThe Lancet Neurology, 2019
- Oxygen Extraction Fraction and Stroke Risk in Patients with Carotid Stenosis or Occlusion: A Systematic Review and Meta-AnalysisAmerican Journal of Neuroradiology, 2013
- Extracranial-Intracranial Bypass Surgery for Stroke Prevention in Hemodynamic Cerebral IschemiaJAMA, 2011